title: Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
abstract: The true potential of cytokine therapies in cancer treatment is limited by the inability to deliver optimal concentrations into tumor sites due to dose-limiting systemic toxicities. To maximize the efficacy of cytokine therapy, recombinant antibody-cytokine fusion proteins have been constructed by a number of groups to harness the tumor-targeting ability of monoclonal antibodies. The aim is to guide cytokines specifically to tumor sites where they might stimulate more optimal anti-tumor immune responses while avoiding the systemic toxicities of free cytokine therapy. Antibody-cytokine fusion proteins containing interleukin (IL)-2, IL-12, IL-21, tumor necrosis factor (TNF)α, and interferons (IFNs) α, β, and γ have been constructed and have shown anti-tumor activity in preclinical and early-phase clinical studies. Future priorities for development of this technology include optimization of tumor targeting, bioactivity of the fused cytokine, and choice of appropriate agents for combination therapies. This review is intended to serve as a framework for engineering an ideal antibody-cytokine fusion protein, focusing on previously developed constructs and their clinical trial results.
authors.affiliation: Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA.
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Young
authors.affiliation: Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA.
authors.forename: Sherie L
authors.initials: SL
authors.lastname: Morrison
authors.affiliation: Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA. Electronic address: jtimmerman@mednet.ucla.edu.
authors.forename: John M
authors.initials: JM
authors.lastname: Timmerman
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D016207:Cytokines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D015202:Protein Engineering; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use*; D012449:Safety
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D011993:Recombinant Fusion Proteins